Answers are grounded in this paper and cite their sources.
Prospective single-arm study demonstrates 100% technical feasibility for immediate preventive lymphaticovenous anastomosis during axillary dissection, indicating effective vein-selection guidance.
This single-center, prospective, single-arm technical feasibility study evaluated the technical executability of a predefined Type I/II/III recipient vein-selection strategy and immediate fluorescence-confirmed patency during immediate preventive lymphaticovenous anastomosis (LVA) performed with axillary lymph node dissection (ALND). Perioperative outcomes and clinical follow-up findings were evaluated as secondary descriptive observations. From October 2024 to December 2024, 30 female patients with unilateral breast cancer who underwent clinically indicated ALND were prospectively enrolled after ethics approval. All patients underwent baseline assessment for breast cancer-related lymphedema (BCRL) before surgery. Immediate preventive LVA was performed during ALND using the predefined Type I/II/III recipient vein-selection strategy without altering the planned oncologic resection. The primary endpoints were strategy executability, defined as successful identification, preservation, and use of an appropriate recipient vein for LVA, and immediate intraoperative patency, confirmed by fluorescence imaging demonstrating lymphatic-to-venous drainage after anastomosis. Secondary endpoints included perioperative complications, BCRL events, and descriptive locoregional oncologic observations. Target recipient veins were successfully identified, preserved, and used to complete LVA in all 30 patients, yielding a technical execution success rate of 30/30 (100%). Type I veins were used in 21 patients (70.0%), Type II veins in 3 patients (10.0%), combined Type I/II veins in 5 patients (16.7%), and Type III veins in 1 patient (3.3%). Intraoperative fluorescence imaging demonstrated lymphatic-to-venous drainage after anastomosis in all patients, without obvious venous reflux, leakage, or obstruction. No perioperative complications, including bleeding, lymphatic leakage, surgical-site infection, or upper-limb lymphangitis, were observed. During follow-up at 6, 12, and 18 months, no BCRL event, locoregional recurrence, or adverse oncologic event related to recipient vein preservation or LVA was observed. These follow-up findings were treated as descriptive observations only and were not used to infer preventive efficacy or established oncologic safety. The predefined Type I/II/III recipient vein-selection strategy was technically executable in all 30 patients, with immediate fluorescence-confirmed lymphatic-to-venous drainage after LVA in all cases and no observed perioperative complications. These findings support the technical feasibility of this structured recipient vein-selection framework within an experienced microsurgical team. The absence of BCRL, locoregional recurrence, and LVA-related adverse events during the 18-month follow-up should be interpreted strictly as descriptive observations and does not establish preventive efficacy or oncologic safety. External reproducibility, generalizability, the learning curve, and preventive efficacy require further evaluation in appropriately designed multicenter prospective studies, including controlled studies for efficacy assessment.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: